phosphoenolpyruvate decarboxylase Inhibitors
2 drugsAbout phosphoenolpyruvate decarboxylase
Phosphoenolpyruvate decarboxylase (PEPC) catalyzes the irreversible decarboxylation of phosphoenolpyruvate. Its precise biological function and mechanism of action require further research to fully elucidate its therapeutic potential.
Currently, there is no genetic evidence directly linking PEPC to specific diseases. However, the existence of two FDA-approved drugs targeting PEPC suggests potential therapeutic relevance.
PEPC is targeted by two FDA-approved small molecule drugs: MULTRYS and TRALEMENT, both marketed by AM REGENT. These drugs are classified under "Other" therapeutic areas.
Top phosphoenolpyruvate decarboxylase Drugs
AM REGENT is the only company with approved drugs targeting PEPC.
Low competition represents an opportunity, but also a risk due to single-player dependency.
phosphoenolpyruvate decarboxylase Drug Modality Landscape
Modalities
Routes of Administration
phosphoenolpyruvate decarboxylase is druggable by small molecules, though no oral formulations are currently approved.
The exclusive use of small molecules suggests an opportunity for novel modalities like antibodies.
phosphoenolpyruvate decarboxylase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on phosphoenolpyruvate decarboxylase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
phosphoenolpyruvate decarboxylase Drug Approval Timeline (2020 - 2020)
The first drug targeting PEPC was approved in 2020, with the most recent approval also in 2020.
Recent approvals indicate renewed interest, but short timespan suggests market is nascent.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on phosphoenolpyruvate decarboxylase. A trial counts if an approved drug acting on phosphoenolpyruvate decarboxylase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.